The Laotian Times Hyundai Bioscience Confirms Entry into U.S. FDA Phase 2 Trials for Broad-Spectrum Antiviral ‘XAFTY’ Following 2026 Biotech Showcase Consensus
– UCSD’s Dr. Davey Smith, former ACTIV-2 Protocol Chair, endorses ‘Xafty’ as “The weapon to end the virus war.” – Announces “One Drug, Two Tracks” strategy: Targeting Dengue in Vietnam and Respiratory Viruses (Flu, COVID, RSV) in the U.S. with the same drug. – Dr. Davey Smith: “With this multi-virus treatment, 2026 may mark the inaugural year […]